The status of clinical trials: Cause for concern

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Nussenblatt, Robert B ^a   Meinert, Curtis L ^b  

^a NATIONAL EYE INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; CLINICAL STUDY; HEALTH CARE POLICY; MEDICAL EDUCATION; NATIONAL HEALTH ORGANIZATION; NOTE; PROGRAM DEVELOPMENT; PUBLIC-PRIVATE PARTNERSHIP; STUDY DESIGN; ARTICLE; CLINICAL TRIAL; HUMAN; STATISTICS; UNITED STATES;

CLINICAL TRIALS AS TOPIC; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); UNITED STATES;

EID: 77954274735     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-65     Document Type: Note

References (14)

1. Pharmaceutical Research and Manufacturers of America Biopharmaceutical Industry Investment in Research and Development 1980-2004. 2005, Pharmaceutical Research and Manufacturers of America., Http://www.phrma.org
2. Pinn VW, Roth C, Bates AC, Wagner R, Jarema K. 2009, Department of Health and Human Services. National Institutes of Health, Monitoring Adherence to the NIH policy on the Inclusion of Women and Minorities as Subjects in Clinical Research. Comprehensive Report: Tracking of Human Subjects Research in Fiscal Year 2007 and Fiscal Year 2008.
3. National Institutes of Health. , http://www.nih.gov/news/crp/97report/execsum.htm
4. Pinn VW, Roth C, Bates AC, Caban CE, Jarema K. 2005, Department of Health and Human Services. National Institutes of Health, Monitoring Adherence to the NIH policy on the inclusion of women and minorities as subjects in clinical research. Comprehensive report: Tracking of human subjects research as reported in fiscal year 2003 and fiscal year 2004.
5. Nathan DG, Varmus HE. The National Institutes of Health and clinical research: a progress report. Nature Medicine 2000, 6(11):1201-1204. 10.1038/81282, 11062519.
6. Goldstein JL, Brown MS. The Clinical Investigator, Bewitched, Bothered, and Bewildered-but still Beloved. J Clin Invest 1997, 99(12):2803-2812. 10.1172/JCI119470, 508127, 9185499.
7. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analysis of new drugs used in oncology. JAMA 1999, 282(15):1453-7. 10.1001/jama.282.15.1453, 10535436.
8. Angell M. Excess in the Pharmaceutical Industry. Canadian Medical Association Journal 2004, 171:1451-1453. 10.1503/cmaj.1041594, 534578, 15583183.
9. US Food and Drug Administration Center for Drug Evaluation and Research NDAs approved in calendar years 1990-2003 by therapeutic potentials and chemical types. 2004, US Food and Drug Administration Center for Drug Evaluation and Research., Http://www.fda.gov/cder/rdmt/pstable.htm
10. Rehnquist J, . Office of the Inspector General The Globalization of Clinical Trials. 2001, A Growing Challenge in Protecting Human Subjects, US Department of Health and Human Services, Editor, Office of the Inspector General.
11. Meinert C. Randomized Trials vs. Epidemiology?. Presented at the 16th Annual Meeting of the Society for Pediatric and Perinatal Epidemiologic Research (SPER). Atlanta, Georgia 2003,
12. Zerhouni EA. The NIH Roadmap. Science 2003, 302:63-64. 72, 10.1126/science.1091867, 14526066.
13. Zerhouni EA. Translational and Clinical Science-Time for a New Vision. New England Journal of Medicine 2005, 353:1621-1623. 10.1056/NEJMsb053723, 16221788.
14. Clinical and Translational Science Awards (Consortium) Accessed 3-31-10, Clinical and Translational Science Awards (Consortium)., http://www.ncrr.nih.gov/clinicaldiscipline.asp